DARK, Unrefined, full-spectrum CBD contains the MOST cannabinoids, the MOST terpenes, and the MOST plant nutrients over any GOLDEN REFINED oil. NOIDS™ – (32-CT-SOFTGELS) 800MG CBD
We keep it REAL dark, REAL raw and REAL potent.
UNREFINED = REAL RESULTS!
Grab yourself some NOIDS and keep it RAW, the way nature intended. NOIDS™ – (32-CT-SOFTGELS) 800MG CBD
Welcome to NOIDS™ by CBD For The People. NOIDS™ – (32-CT-SOFTGELS) 800MG CBD
“The RAWEST, most POTENT CBD capsules on the market.”
Why are they SO DARK you say? Because they’re made of 100% UNREFINED full-spectrum CBD! 100% chemical and preservative FREE!
Full-spectrum CBD is NOT created equal. CBD is DARK when extracted from the hemp plant. This is the RAW, UNREFINED state. It takes a lot of refining to make the oil GOLDEN and PRETTY like most other companies on the market. Cannabinoids, nutrients, and terpenes are LOST at EVERY STAGE of the refining process. Basically, the darker the oil the better! NOIDS™ – (32-CT-SOFTGELS) 800MG CBD
Considering data from in vitro and in vivo studies, cannabidiol (CBD) seems to be a promising candidate for the treatment of both somatic and psychiatric disorders. The aim of this review was to collect dose(s), dosage schemes, efficacy and safety reports of CBD use in adults from clinical studies. A systematic search was performed in PubMed, Embase and Cochrane library for articles published in English between January 1, 2000 and October 25, 2019. The search terms used were related to cannabis and CBD in adults. We identified 25 studies (927 patients; 538 men and 389 women), of which 22 studies were controlled clinical trials (833 patients) and three were observational designs (94 patients) from five countries. Formulations, dose and dosage schemes varied significantly between studies. Varying effects were identified from the randomized controlled trials (RCTs), more apparent effects from non-RCTs and minor safety issues in general. From the controlled trials, we identified anxiolytic effects with acute CBD administration, and therapeutic effects for social anxiety disorder, psychotic disorder and substance use disorders. In general, studies were heterogeneous and showed substantial risks of bias. Although promising results have been identified, considerable variation in dosage schemes and route of administration were employed across studies. There was evidence to support single dose positive effect on social anxiety disorder, short medium-term effects on symptomatic improvement in schizophrenia and lack of effect in the short medium-term on cognitive functioning in psychotic disorders. Overall, the administration was well tolerated with mild side effects. NOIDS™ – (32-CT-SOFTGELS) 800MG CBD